Search

Edoxudine

[A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113] … It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus.

Sodium ascorbate

Rosin

Rosin has shown to mediate antibacterial actions on Gram-positive bacterial species [A27267]. … In the pharmaceuticals, rosin is used in film forming and coating tablets and enterically administered agents, as well as forming microcapsules and nanoparticles.

Galactose

Regardless, although it is predominantly used as a pathway to generate glucose fuel for the human body, galactose is involved as an ingredient in some commonly used vaccines and non-prescription products … There are even proposals for its use in accelerating senescence in mice, rats, and Drosophila, for its association with ovarian cancer, or even for the potential treatment of focal segmental glomerulosclerosis

Trimethadione

An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)

Nirsevimab

[L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.

Sodium borate

Citrus bioflavonoids

Deslanoside

Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.

Octreotide

On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. … [L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor.